Citigroup Maintains Buy on Tenet Healthcare, Raises Price Target to $171
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Jason Cassorla maintains a Buy rating on Tenet Healthcare (NYSE:THC) and raises the price target from $139 to $171.
July 25, 2024 | 5:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup analyst Jason Cassorla maintains a Buy rating on Tenet Healthcare and raises the price target from $139 to $171.
The raised price target from $139 to $171 by Citigroup indicates a positive outlook for Tenet Healthcare, likely leading to increased investor confidence and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100